首页> 美国卫生研究院文献>Oncotarget >A six-long non-coding RNAs signature as a potential prognostic marker for survival prediction of ER-positive breast cancer patients
【2h】

A six-long non-coding RNAs signature as a potential prognostic marker for survival prediction of ER-positive breast cancer patients

机译:六长非编码RNA信号作为ER阳性乳腺癌患者生存预测的潜在预后标记

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Dysregulated expression of lncRNAs has been observed in various human complex diseases (including cancers) by recent transcriptional profiling studies, highlighting potentials of lncRNAs as biomarkers for cancer diagnosis and prognosis. Despite some efforts have been made to search for novel lncRNA signature in breast cancer, the prognostic value of lncRNAs for ER-positive breast cancer patients still needs to be systematically investigated. In this study, we analyzed lncRNA expression profiles in a large of more than 600 breast cancer patients with ER-positive status from The Cancer Genome Atlas (TCGA) and identified six lncRNAs that are significantly associated with survival. Then a linear risk score model comprising six prognostic lncRNAs, termed six-lncRNA signature, was developed to identify high-risk patients from low-risk cases. The results of Kaplan-Meier analysis and ROC curves demonstrated the good sensitivity and specificity in survival prediction both in the training and testing datasets. Multivariate Cox regression analysis and stratified analysis showed that the six-lncRNA signature is an independent prognostic marker in survival prediction for ER-positive breast cancer patients. The GO enrichment analysis suggested that the six-lncRNA might involve with known breast cancer-related biological processes. With further experimental validation, these identified prognostic lncRNAs might have clinical implications for more personalized risk assessment for ER-positive breast cancer patients.
机译:最近的转录谱研究已在各种人类复杂疾病(包括癌症)中观察到lncRNA表达失调,突出了lncRNA作为生物标志物在癌症诊断和预后方面的潜力。尽管已经进行了一些努力来寻找乳腺癌中新的lncRNA特征,但是仍需要系统地研究lncRNA对ER阳性乳腺癌患者的预后价值。在这项研究中,我们分析了来自癌症基因组图谱(TCGA)的600多名具有ER阳性状态的乳腺癌患者中的lncRNA表达谱,并鉴定了6个与存活率显着相关的lncRNA。然后,开发了一个包含六个预后的lncRNA的线性风险评分模型,称为6-lncRNA特征,以从低风险病例中识别高风险患者。 Kaplan-Meier分析和ROC曲线的结果表明,在训练和测试数据集中,生存预测具有良好的敏感性和特异性。多变量Cox回归分析和分层分析表明,六价-lncRNA标志是ER阳性乳腺癌患者生存预测的独立预后标志物。 GO富集分析表明6-lncRNA可能与已知的乳腺癌相关生物学过程有关。通过进一步的实验验证,这些鉴定出的预后性lncRNA可能对ER阳性乳腺癌患者进行更具个性化的风险评估具有临床意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号